The “Green Rush”
Market exposure to the growing cannabis industry

5 minute read - from V.E

January 2021
INTRODUCTION

In December 2020, the UN Commission on Narcotic Drugs reclassified cannabis out of the most dangerous category of drugs, thus recognising its medicinal potential.¹ In the same month, the United States House of Representatives voted to effectively legalise recreational cannabis at the federal level.² These actions consolidated the progressive deliberations reached at state level in terms of legislation, beginning with Washington, which legalised recreational cannabis in December 2012.³ Many other states and several countries have since followed suit. This legislative and regulatory evolution has led to an explosion of investment in the cannabis sector.⁴ In this quick read, Vigeo Eiris (V.E) summarises why cannabis production and use remain controversial and assesses how investors may be exposed to reputational risks.

CONTEXT

According to the World Health Organisation (WHO), cannabis is the most cultivated, trafficked, and abused illegal drug in the world; around 2.5% of the global population consume cannabis.⁵ Cannabis use can have negative health impacts, especially when smoked with tobacco, as this can increase the likelihood of tobacco-related diseases, such as cancer. Regular cannabis users also risk developing psychotic illnesses, such as schizophrenia, as well as cardiovascular disease and increasing the likelihood of having a stroke.⁶ However, research suggests the latter conditions are caused by the cannabis smoke, rather than the plant’s active ingredients.⁷

Cannabis contains active ingredients called cannabinoids. Two of these — tetrahydrocannabinol (THC) and cannabidiol (CBD) — are found in a range of prescription drugs, including Sativex, which is used to relieve the pain of muscle spasms in multiple sclerosis sufferers. Trials are under way to test cannabis-based drugs for a range of other health conditions, including cancer pain.

¹ “UN commission reclassifies cannabis, yet still considered harmful” – UN News – 02/12/2020
² “Pot Legalization Bill Passes House, But Senate Vote Unlikely” – Bloomberg – 04/12/2020
³ “Marijuana goes legal in Washington state amid mixed messages” – Reuters – 06/12/2012
⁴ “Key Insights from the Global Cannabis Report” – Prohibition Partners – 07/11/2019
⁵ “Cannabis” – World Health Organization, Alcohol, Drugs and Addictive Behaviours Unit – accessed 09/12/2020
⁶ “Cannabis: the facts” – UK NHS – accessed 09/12/2020
⁷ “Marijuana and heart health: What you need to know” – Harvard Health publishing – 24/06/2019
and appetite loss in people with HIV or AIDS.\textsuperscript{8} That said, THC-containing products remain more tightly controlled in many areas due to their psychoactive effects.\textsuperscript{9}

**Evolving Legal Landscape**

The legalisation of cannabis is supported by many economically developed countries and aims to tackle the illicit market by creating a commercial, regulated market where competitive forces drive down prices and costs, undercutting the illegal market.

In 2013, Uruguay became the first country to legalise recreational cannabis, whilst Canada became the first G7 country to do so in 2018.\textsuperscript{10} In the U.S., 15 states and Washington DC have legalised marijuana for adults over the age of 21, whilst 36 states have legalised medical marijuana.\textsuperscript{11} However, cannabis remains illegal under federal law, a situation that might change following the recent vote to effectively legalise recreational cannabis at the federal level by the House of Representatives.\textsuperscript{12}

**Legality of Medical Cannabis**\textsuperscript{13}

---

\textsuperscript{8} “Cannabis: the facts” – UK NHS – accessed 09/12/2020
\textsuperscript{9} The Global Cannabis Report – Prohibition Partners – November 2019 – p23
\textsuperscript{10} “Countries Where Cannabis Is Legal” – WorldAtlas – 27/05/2020
\textsuperscript{11} “All the states where marijuana is legal — and 5 more that voted to legalize it in November” – Business Insider – 06/01/2021
\textsuperscript{12} Pot Legalization Bill Passes House, But Senate Vote Unlikely” – Bloomberg – 04/12/2020
\textsuperscript{13} “Cannabis Legalisation: Where is Medicinal Cannabis Legal in the World?” – Canex – 19/08/2020
In Europe, activism by families of children with severe forms of epilepsy prompted the UK government to define new ways for doctors to prescribe cannabis-based medicinal products (CBMPs) from November 2018.14 Meanwhile, Luxembourg is set to become the first European country to legalise recreational cannabis (medical cannabis was legalised in June 2018).15 Additionally, in December 2018, Thailand became the first country to approve medical cannabis in Southeast Asia. Support for similar reforms has subsequently increased in neighbouring countries.16

A BOOMING SECTOR

Due to the aforementioned changes, the cannabis industry is booming. In 2019, the global legal cannabis market was valued at USD 17.7 billion.17 According to Prohibition Partners, it is set to be worth almost USD 104 billion by 2024, driven primarily by the medicinal cannabis market.18 The UK is the world’s largest producer and exporter of medicinal cannabis.19 Predictably, therefore, over half of Europe’s cannabis market will be derived from medical cannabis.20

Forecasted Global Legal Cannabis Market Size, 2024 (US$) 21

14 “United Kingdom Medical Cannabis Regulations Enter into Force” – Hanway Associates – 01/11/2018
15 “Luxembourg to be first European country to legalise cannabis” – The Guardian – 07/08/2019
16 “Key Insights from the Global Cannabis Report” – Prohibition Partners – 07/11/2019
18 “Key Insights from the Global Cannabis Report” – Prohibition Partners – 07/11/2019
19 “UK world’s largest producer of legal cannabis, finds UN body” – Independent – 07/03/2018
20 “Key Insights from the Global Cannabis Report” – Prohibition Partners – 07/11/2019
21 Ibid
Despite the industry’s growth, the lack of legal and regulatory uniformity within and between countries can make it difficult for investors to assess their exposure to the burgeoning market.

**V.E RESEARCH FINDINGS**

V.E has screened over 7,700 issuers for their involvement in the cannabis industry. Of these, 37 (0.5% of the screened universe) appear to be involved, as of December 2020. The most exposed sector is the Pharmaceutical and Biotechnology sector (24% of involved issuers), followed by the Beverage sector (16% of involved issuers), and the Tobacco, Chemicals, and Software and IT Services sectors, which are all equally represented (11% of involved issuers in each).

Geographically, North American issuers dominate, with 43% of the companies involved based in the U.S. and 19% based in Canada. This is unsurprising considering the relatively recent legal changes in the two countries. Meanwhile, a further 32% of involved issuers are European.

To measure involvement, V.E differentiates between production (namely the ownership of cannabis plantations and the manufacturing of recreational cannabis products), distribution (those involved in the wholesaling and retail of cannabis products manufactured by other companies), and the provision of essential equipment or services to the recreational cannabis industry. V.E has found that 32% of the issuers involved are producers, whilst 8% are distributors, and 46% supply equipment/services. V.E can also identify those issuers involved in medicinal cannabis (19% of those issuers involved).

**CONCLUSIONS**

The legislative evolution of both medicinal and recreational cannabis around the world has led to a surge in growth within the sector. However, cannabis production and use remain a subject of controversy and public debate, primarily due to the associated negative health implications. Given the varying views and perceptions around cannabis use across geographies and the developing regulatory and commercial landscape, it is important investors understand their potential exposure. Our analysis demonstrates the risk exposure is limited to a small subset of companies, primarily concentrated in the Pharmaceutical and Biotechnology and Beverage sectors. The issuers involved are overwhelmingly located in North America and Western Europe.
AUTHORS

IANELA ORTIZ, HEAD OF SPECIALISED RESEARCH, ianela.ortiz@vigeo-eiris.com
ALESSANDRO BRACAGLIA, CAS PRODUCT MANAGER, alessandro.bracaglia@vigeo-eiris.com
JAKE NICHOLSON, CAS CONFIRMED SPECIALISED RESEARCHER, jake.nicholson@vigeo-eiris.com

ABOUT

V.E is a global leader in ESG assessments, data, research, benchmarks and analytics. Leveraging our extensive proprietary database, we equip market players with the ESG insight they need to manage risks and better understand and address their social and environmental impact. With a team of nearly 300 experts of 30 different nationalities, V.E is present in Paris, London, Brussels, Casablanca, Hong Kong, Milan, New York, Rabat and Santiago. Since 2019, V.E has been an Affiliate of Moody’s Corporation.

For more information: vigeo-eiris.com

© 2020 Vigeo SAS and/or its licensors and subsidiaries (collectively, “V.E”). All rights reserved.

V.E provides its customers with data, information, research, analyses, reports, quantitative model-based scores, assessments and/or other opinions (collectively, “Research”) with respect to the environmental, social and/or governance (“ESG”) attributes and/or performance of individual issuers or with respect to sectors, activities, regions, stakeholders, states or specific themes.

V.E’S RESEARCH DOES NOT ADDRESS NON-ESG FACTORS AND/OR RISKS, INCLUDING BUT NOT LIMITED TO: CREDIT RISK, LIQUIDITY RISK, MARKET VALUE RISK; OR PRICE VOLATILITY. V.E’S RESEARCH DOES NOT CONSTITUTE STATEMENTS OF CURRENT OR HISTORICAL FACT. V.E’S RESEARCH: (i) DOES NOT CONSTITUTE OR PROVIDE CREDIT RATINGS OR INVESTMENT OR FINANCIAL ADVICE; (ii) IS NOT AND DOES NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES; AND (iii) DOES NOT COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. V.E ISSUES ITS RESEARCH WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

V.E’S RESEARCH IS NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE V.E’S RESEARCH WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER. V.E’S RESEARCH IS NOT INTENDED FOR USE BY ANY PERSON AS A BENCHMARK AS THAT TERM IS DEFINED FOR REGULATORY PURPOSES AND MUST NOT BE USED IN ANY WAY THAT COULD RESULT IN THEM BEING CONSIDERED A BENCHMARK.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT V.E’S PRIOR WRITTEN CONSENT.

To the extent permitted by law, V.E and its directors, officers, employees, agents, representatives, licensors and suppliers (together, “V.E Parties”) disclaim liability to any person or entity for any (a) indirect, special, consequential, or incidental losses or damages, and (b) direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded), on the part of, or any contingency within or beyond the control of any V.E Party, arising from or in connection with the information contained herein or the use of or inability to use any such information.

Additional terms For PRC only: Any Second Party Opinion or other opinion issued by V.E: (1) does not constitute a PRC Green Bond Assessment as defined under any relevant PRC laws or regulations; (2) cannot be included in any registration statement, offering circular, prospectus or any other documents submitted to the PRC regulatory authorities or otherwise used to satisfy any PRC regulatory disclosure requirement; and (3) cannot be used within the PRC for any regulatory purpose or for any other purpose which is not permitted under relevant PRC laws or regulations. For the purposes of this disclaimer, “PRC” refers to the mainland of the People’s Republic of China, excluding Hong Kong, Macau and Taiwan.